At two upcoming investor conferences, our management team will discuss upcoming milestones and how we are leveraging the power of #celltherapy for patients with #autoimmunediseases. Information here: https://bit.ly/46ZxSEc
Cartesian Therapeutics
Biotechnology Research
Gaithersburg, MD 3,957 followers
Pioneering RNA cell therapy for autoimmune disease
About us
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Gaithersburg, MD
- Type
- Public Company
- Founded
- 2016
- Specialties
- Immunotherapy, Oncology, Molecular Biology, Immunology, Autoimmune Diseases, Myasthenia Gravis, ARDS, Cell Therapy, Lung disease, NETs, Cardiovascular Disease, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, and CAR-T
Locations
-
Primary
Get directions
Gaithersburg, MD 20878, US
Employees at Cartesian Therapeutics
-
Christopher M. Jewell
Chief Scientific Officer, Cartesian Therapeutics | MPower Professor and Institute Professor of Translational Engineering | Biotechnology Consultant
-
Heng Xu
Research Scientist at Cartesian Therapeutics
-
Jessica Keliher, SPHR
Chief People Officer & Executive Leadership Coach
-
Carsten Brunn
President and CEO
Updates
-
Join us at next week’s Cell & Gene Live event discussing modernizing CAR-T manufacturing, where Cartesian’s Emily English will speak about the challenges, opportunities, and future of CAR-T cell therapies. Register here: https://bit.ly/4cn8Lwc
-
-
Today we reported second quarter 2024 financial results and provided a business update. Full press release: https://bit.ly/4dSMd7Z #celltherapy #autoimmunity
-
-
Tune in today to hear from Emily English on mRNA quality guidelines and how Cartesian is applying these to our pipeline of mRNA cell therapy programs for #autoimmune diseases. Register here: https://bit.ly/3y6O4qx
-
-
This morning, Cartesian CSO Christopher M. Jewell is presenting on the benefits of RNA cell therapy for patients with #autoimmune diseases and the latest data from our pipeline of mRNA CAR-T programs. Register here: https://bit.ly/3y6O4qx
-
-
Happening next week: Cartesian team members Christopher M. Jewell and Emily English are presenting at the 4th mRNA-Based Therapeutics Summit on understanding mRNA cell therapy and how Cartesian is expanding the reach to #autoimmune diseases. We hope to see you there!
-
-
Thank you to everyone who attended our educational session at #AANSC on the benefits of mRNA CAR-T therapy and highlights from our recently completed Phase 2b trial of Descartes-08 in #myastheniagravis. Learn more about our science: https://bit.ly/3Qr2LdY
-
-
This Friday at #AANSC, Cartesian is sponsoring an educational session discussing the differences between conventional and mRNA CAR-T therapy and highlighting the key findings from Cartesian’s recently completed Phase 2b trial of Descartes-08 in #myastheniagravis. Full details: https://bit.ly/3zFNosq
-
-
Welcome Dr. Kemal Malik to our Board of Directors! An accomplished industry executive with 30 years of experience in global pharmaceutical research, Dr. Malik’s deep expertise will be invaluable as we expand the reach of cell therapy to #autoimmunity. Read here: https://bit.ly/45RblsM
-
-
We recently announced dosing of the first patient in our Phase 2 trial of Descartes-08 in patients with #SLE. Cartesian’s approach is designed to overcome the limitations of conventional DNA-engineered CAR-T cell therapies for #autoimmunediseases. Read more: https://bit.ly/3Wbmku4
-